Actinium Pharmaceuticals Inc (AMEX:ATNM)’s traded shares stood at 0.6 million during the last session, with the company’s beta value hitting -0.17. At the close of trading, the stock’s price was $1.55, to imply an increase of 9.93% or $0.14 in intraday trading. The ATNM share’s 52-week high remains $10.24, putting it -560.65% down since that peak but still an impressive 33.55% since price per share fell to its 52-week low of $1.03. The company has a valuation of $48.36M, with an average of 0.37 million shares in intraday trading volume over the past 10 days and average of 227.00K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Actinium Pharmaceuticals Inc (ATNM), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give ATNM a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.39.
Actinium Pharmaceuticals Inc (AMEX:ATNM) trade information
After registering a 9.93% upside in the last session, Actinium Pharmaceuticals Inc (ATNM) has traded red over the past five days. The 5-day price performance for the stock is 26.02%, and 26.02% over 30 days. With these gigs, the year-to-date price performance is 23.02%. Short interest in Actinium Pharmaceuticals Inc (AMEX:ATNM) saw shorts transact 2.25 million shares and set a 13.64 days time to cover.
The extremes give us $4 and $24.26 for target low and target high price respectively. As such, ATNM has been trading -1465.16% off suggested target high and -158.06% from its likely low.
Actinium Pharmaceuticals Inc (ATNM) estimates and forecasts
The rating firms project that company’s revenue will shrink -100.00% compared to the previous financial year.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 22.80% for the past 5-year period. While 2025 is set for a 34.00% return in earnings, projections for the next 5 years are at 13.33% annually.
ATNM Dividends
Actinium Pharmaceuticals Inc has its next earnings report out on 2024-Nov-13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Actinium Pharmaceuticals Inc (AMEX:ATNM)’s Major holders
Actinium Pharmaceuticals Inc insiders hold 1.79% of total outstanding shares, with institutional holders owning 29.67% of the shares at 30.21% float percentage. In total, 29.67% institutions holds shares in the company, led by ADAR1 CAPITAL MANAGEMENT, LLC. As of 2024-06-30, the company held over 75133.0 shares (or 0.2496% of shares), all amounting to roughly $0.56 million.
The next major institution holding the largest number of shares is ROYCE & ASSOCIATES LP with 50000.0 shares, or about 0.1661% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $0.37 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Actinium Pharmaceuticals Inc (ATNM) shares. Going by data provided on Dec 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 938.63 shares. This is just over 3.01% of the total shares, with a market valuation of $1.45 million. Data from the same date shows that the other fund manager holds a little less at 816.68, or 2.62% of the shares, all valued at about 1.27 million.
